Targeting cell death in the reperfused heart: Pharmacological approaches for cardioprotection

International Journal of Cardiology

Volumn 165, Issue 3, 2013, Pages 410-422

  Oerlemans, Martinus I F J ^a   Koudstaal, Stefan ^a,b   Chamuleau, Steven A ^a,b   De Kleijn, Dominique P ^a,b   Doevendans, Pieter A ^a,b   Sluijter, Joost P G ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Cardioprotection; Cell death; Myocardial infarction; Pharmacological postconditioning; Reperfusion injury

Indexed keywords

ADENOSINE; ALISPORIVIR; ATRIAL NATRIURETIC FACTOR; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CALDARET; CASPASE 3; CASPASE 4; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CREATINE KINASE MB; CYCLOSPORIN A; EXENDIN 4; GLYCERYL TRINITRATE; IDN 6734; INTERLEUKIN 1BETA CONVERTING ENZYME; ISOSORBIDE DINITRATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MONOCLONAL ANTIBODY; NECROSTATIN 1; PLACEBO; PROTEIN SERINE THREONINE KINASE INHIBITOR; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; SANGLIFEHRIN A; SERINE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR 2; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG; ATRIAL NATRIURETIC FACTOR DERIVATIVE; CASPASE 1 INHIBITOR; CASPASE 10; CASPASE 2; CASPASE 3 INHIBITOR; CASPASE 4 INHIBITOR; CASPASE 7 INHIBITOR; CASPASE 8 INHIBITOR; CASPASE 9 INHIBITOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN;

ACUTE HEART INFARCTION; APOPTOSIS; CELL DEATH; CELL LOSS; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS SURGERY; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; MOUSE; MULTICENTER STUDY (TOPIC); NECROPTOSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RABBIT; RAT; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADJUVANT THERAPY; BYPASS SURGERY; DNA FRAGMENTATION; FOLLOW UP; IN VITRO STUDY; IN VIVO STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; REPERFUSION INJURY; TRAUMATIC BRAIN INJURY;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CASPASE INHIBITORS; CELL DEATH; DRUG DELIVERY SYSTEMS; HUMANS; MYOCARDIAL REPERFUSION INJURY;

EID: 84877011174     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.055     Document Type: Review

References (215)

1. D. Lloyd-Jones, R.J. Adams, and T.M. Brown Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
2. R.G. McKay, M.A. Pfeffer, and R.C. Pasternak Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion Circulation 74 1986 693 702
3. B.E. Sobel, G.F. Bresnahan, W.E. Shell, and R.D. Yoder Estimation of infarct size in man and its relation to prognosis Circulation 46 1972 640 648
4. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
5. D. Garcia-Dorado, M. Ruiz-Meana, and H.M. Piper Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues Cardiovasc Res 83 2009 165 168
6. A. Prasad, G.W. Stone, D.R. Holmes, and B. Gersh Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion Circulation 120 2009 2105 2112
7. M. Ovize, G.F. Baxter, and L.F. Di Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology Cardiovasc Res 87 2010 406 423
8. L. Schwartz Longacre, R.A. Kloner, and A.E. Arai New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop Circulation 124 2011 1172 1179
9. D.J. Hausenloy, G. Baxter, and R. Bell Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations Basic Res Cardiol 105 2010 677 686
10. T. Miura, and T. Miki Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy Basic Res Cardiol 103 2008 501 513
11. E. Murphy, and C. Steenbergen Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury Physiol Rev 88 2008 581 609
12. G. Kroemer, L. Galluzzi, and P. Vandenabeele Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 Cell Death Differ 16 2009 3 11
13. B. Levine, and G. Kroemer Autophagy in the pathogenesis of disease Cell 132 2008 27 42
14. R.A. Gottlieb, and R.M. Mentzer Autophagy during cardiac stress: joys and frustrations of autophagy Annu Rev Physiol 72 2010 45 59
15. J. Kajstura, W. Cheng, and K. Reiss Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats Lab Invest 74 1996 86 107
16. S. Bialik, D.L. Geenen, and I.E. Sasson Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53 J Clin Invest 100 1997 1363 1372
17. T. Scarabelli, A. Stephanou, and N. Rayment Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury Circulation 104 2001 253 256
18. E. Palojoki, A. Saraste, and A. Eriksson Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats Am J Physiol Heart Circ Physiol 280 2001 H2726 H2731
19. E.A. Dumont, L. Hofstra, and W.L. van Heerde Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model Circulation 102 2000 1564 1568
20. E.A. Dumont, C.P. Reutelingsperger, and J.F. Smits Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart Nat Med 7 2001 1352 1355
21. R.A. Gottlieb, K.O. Burleson, R.A. Kloner, B.M. Babior, and R.L. Engler Reperfusion injury induces apoptosis in rabbit cardiomyocytes J Clin Invest 94 1994 1621 1628
22. H. Fliss, and D. Gattinger Apoptosis in ischemic and reperfused rat myocardium Circ Res 79 1996 949 956
23. L. Hofstra, I.H. Liem, and E.A. Dumont Visualisation of cell death in vivo in patients with acute myocardial infarction Lancet 356 2000 209 212
24. J.P. Cleutjens, W.M. Blankesteijn, M.J. Daemen, and J.F. Smits The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions Cardiovasc Res 44 1999 232 241
25. N.G. Frangogiannis The mechanistic basis of infarct healing Antioxid Redox Signal 8 2006 1907 1939
26. R.S. Whelan, V. Kaplinskiy, and R.N. Kitsis Cell death in the pathogenesis of heart disease: mechanisms and significance Annu Rev Physiol 72 2010 19 44
27. G. Kung, K. Konstantinidis, and R.N. Kitsis Programmed necrosis, not apoptosis, in the heart Circ Res 108 2011 1017 1036
28. F. Di Lisa, A. Carpi, V. Giorgio, and P. Bernardi The mitochondrial permeability transition pore and cyclophilin D in cardioprotection Biochim Biophys Acta 1813 2011 1316 1322
29. C.P. Baines, R.A. Kaiser, and N.H. Purcell Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death Nature 434 2005 658 662
30. T. Nakagawa, S. Shimizu, and T. Watanabe Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death Nature 434 2005 652 658
31. N. Vanlangenakker, B.T. Vanden, D.V. Krysko, N. Festjens, and P. Vandenabeele Molecular mechanisms and pathophysiology of necrotic cell death Curr Mol Med 8 2008 207 220
32. P. Vandenabeele, L. Galluzzi, T. Vanden Berghe, and G. Kroemer Molecular mechanisms of necroptosis: an ordered cellular explosion Nat Rev Mol Cell Biol 11 2010 700 714
33. A. Degterev, Z. Huang, and M. Boyce Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat Chem Biol 1 2005 112 119
34. A. Degterev, J. Hitomi, and M. Germscheid Identification of RIP1 kinase as a specific cellular target of necrostatins Nat Chem Biol 4 2008 313 321
35. S. Frantz, J. Bauersachs, and G. Ertl Post-infarct remodelling: contribution of wound healing and inflammation Cardiovasc Res 81 2009 474 481
36. A. Diwan, T. Tran, A. Misra, and D.L. Mann Inflammatory mediators and the failing heart: a translational approach Curr Mol Med 3 2003 161 182
37. N.G. Frangogiannis The immune system and cardiac repair Pharmacol Res 58 2008 88 111
38. M. Hori, and K. Nishida Oxidative stress and left ventricular remodelling after myocardial infarction Cardiovasc Res 81 2009 457 464
39. T. Oka, J. Xu, and J.D. Molkentin Re-employment of developmental transcription factors in adult heart disease Semin Cell Dev Biol 18 2007 117 131
40. M. Bujak, and N.G. Frangogiannis The role of TGF-beta signaling in myocardial infarction and cardiac remodeling Cardiovasc Res 74 2007 184 195
41. M.I. Oerlemans, M.J. Goumans, B. van Middelaar, H. Clevers, P.A. Doevendans, and J.P. Sluijter Active Wnt signaling in response to cardiac injury Basic Res Cardiol 105 2010 631 641
42. L. Barandon, F. Casassus, and L. Leroux Secreted frizzled-related protein-1 improves postinfarction scar formation through a modulation of inflammatory response Arterioscler Thromb Vasc Biol 30 2011 e80 e87
43. W.C. Earnshaw, L.M. Martins, and S.H. Kaufmann Mammalian caspases: structure, activation, substrates, and functions during apoptosis Annu Rev Biochem 68 1999 383 424
44. M.O. Hengartner The biochemistry of apoptosis Nature 407 2000 770 776
45. K.M. Regula, and L.A. Kirshenbaum Apoptosis of ventricular myocytes: a means to an end J Mol Cell Cardiol 38 2005 3 13
46. M.T. Crow, K. Mani, Y.J. Nam, and R.N. Kitsis The mitochondrial death pathway and cardiac myocyte apoptosis Circ Res 95 2004 957 970
47. M. van Gurp, N. Festjens, G. van Loo, X. Saelens, and P. Vandenabeele Mitochondrial intermembrane proteins in cell death Biochem Biophys Res Commun 304 2003 487 497
48. M.E. Peter, and P.H. Krammer The CD95(APO-1/Fas) DISC and beyond Cell Death Differ 10 2003 26 35
49. H. Hsu, J. Huang, H.B. Shu, V. Baichwal, and D.V. Goeddel TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex Immunity 4 1996 387 396
50. R.J. Youle, and A. Strasser The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol 9 2008 47 59
51. H. Zou, Y. Li, X. Liu, and X. Wang An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9 J Biol Chem 274 1999 11549 11556
52. K.M. Boatright, and G.S. Salvesen Mechanisms of caspase activation Curr Opin Cell Biol 15 2003 725 731
53. N. Zamzami, and G. Kroemer The mitochondrion in apoptosis: how Pandora's box opens Nat Rev Mol Cell Biol 2 2001 67 71
54. H. Li, H. Zhu, C.J. Xu, and J. Yuan Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis Cell 94 1998 491 501
55. Q.L. Deveraux, N. Roy, and H.R. Stennicke IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases EMBO J 17 1998 2215 2223
56. A.M. Verhagen, P.G. Ekert, and M. Pakusch Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins Cell 102 2000 43 53
57. C. Du, M. Fang, Y. Li, L. Li, and X. Wang Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition Cell 102 2000 33 42
58. Y. Suzuki, Y. Imai, H. Nakayama, K. Takahashi, K. Takio, and R. Takahashi A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death Mol Cell 8 2001 613 621
59. Q.H. Yang, R. Church-Hajduk, J. Ren, M.L. Newton, and C. Du Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis Genes Dev 17 2003 1487 1496
60. T. Koseki, N. Inohara, S. Chen, and G. Nunez ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases Proc Natl Acad Sci U S A 95 1998 5156 5160
61. Y.J. Nam, K. Mani, and A.W. Ashton Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions Mol Cell 15 2004 901 912
62. R.S. Foo, Y.J. Nam, and M.J. Ostreicher Regulation of p53 tetramerization and nuclear export by ARC Proc Natl Acad Sci U S A 104 2007 20826 20831
63. Y.Z. Li, D.Y. Lu, W.Q. Tan, J.X. Wang, and P.F. Li p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC Mol Cell Biol 28 2008 564 574
64. F. Bernassola, A. Ciechanover, and G. Melino The ubiquitin proteasome system and its involvement in cell death pathways Cell Death Differ 17 2010 1 3
65. W. Sohns, T.A. van Veen, and M.A. van der Heyden Regulatory roles of the ubiquitin-proteasome system in cardiomyocyte apoptosis Curr Mol Med 10 2010 1 13
66. M.S. Willis, W.H. Townley-Tilson, E.Y. Kang, J.W. Homeister, and C. Patterson Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease Circ Res 106 2010 463 478
67. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure J Clin Invest 117 2007 2431 2444
68. C. Kitanaka, and Y. Kuchino Caspase-independent programmed cell death with necrotic morphology Cell Death Differ 6 1999 508 515
69. H. Matsumura, Y. Shimizu, Y. Ohsawa, A. Kawahara, Y. Uchiyama, and S. Nagata Necrotic death pathway in Fas receptor signaling J Cell Biol 151 2000 1247 1256
70. N. Holler, R. Zaru, and O. Micheau Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule Nat Immunol 1 2000 489 495
71. A.P. Halestrap What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 46 2009 821 831
72. C. Dahout-Gonzalez, H. Nury, V. Trezeguet, G.J. Lauquin, E. Pebay-Peyroula, and G. Brandolin Molecular, functional, and pathological aspects of the mitochondrial ADP/ATP carrier Physiology (Bethesda) 21 2006 242 249
73. A.P. Halestrap, S.J. Clarke, and S.A. Javadov Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection Cardiovasc Res 61 2004 372 385
74. 2+-dependent pore activated by oxidative stress in heart mitochondria Biochem J 245 1987 915 918
75. A.P. Halestrap, K.Y. Woodfield, and C.P. Connern Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase J Biol Chem 272 1997 3346 3354
76. M. Crompton The mitochondrial permeability transition pore and its role in cell death Biochem J 341 Pt 2 1999 233 249
77. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress Biochem J 255 1988 357 360
78. E.J. Griffiths, and A.P. Halestrap Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin Biochem J 274 Pt 2 1991 611 614
79. D. Vercammen, R. Beyaert, and G. Denecker Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor J Exp Med 187 1998 1477 1485
80. A. Kawahara, Y. Ohsawa, H. Matsumura, Y. Uchiyama, and S. Nagata Caspase-independent cell killing by Fas-associated protein with death domain J Cell Biol 143 1998 1353 1360
81. W. Declercq, T. Vanden Berghe, and P. Vandenabeele RIP kinases at the crossroads of cell death and survival Cell 138 2009 229 232
82. D.J. Mahoney, H.H. Cheung, and R.L. Mrad Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation Proc Natl Acad Sci U S A 105 2008 11778 11783
83. H. Hacker, and M. Karin Regulation and function of IKK and IKK-related kinases Sci STKE 2006 2006 re13
84. L. Wang, F. Du, and X. Wang TNF-alpha induces two distinct caspase-8 activation pathways Cell 133 2008 693 703
85. J. Hitomi, D.E. Christofferson, and A. Ng Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway Cell 135 2008 1311 1323
86. D. Vucic, V.M. Dixit, and I.E. Wertz Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death Nat Rev Mol Cell Biol 12 2011 439 452
87. Y. Lin, A. Devin, Y. Rodriguez, and Z.G. Liu Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis Genes Dev 13 1999 2514 2526
88. N. Vanlangenakker, M.J. Bertrand, P. Bogaert, P. Vandenabeele, and T.V. Berghe TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members Cell Death Dis 2 2011 e230
89. Y.S. Cho, S. Challa, and D. Moquin Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation Cell 137 2009 1112 1123
90. P. Vandenabeele, W. Declercq, F. Van Herreweghe, and T. Vanden Berghe The role of the kinases RIP1 and RIP3 in TNF-induced necrosis Sci Signal 3 2010 re4
91. D.W. Zhang, J. Shao, and J. Lin RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis Science 325 2009 332 336
92. L. Galluzzi, O. Kepp, and G. Kroemer RIP kinases initiate programmed necrosis J Mol Cell Biol 1 2009 8 10
93. F. Van Herreweghe, N. Festjens, W. Declercq, and P. Vandenabeele Tumor necrosis factor-mediated cell death: to break or to burst, that's the question Cell Mol Life Sci 67 2010 1567 1579
94. R.A. Kloner, and L. Schwartz Longacre State of the science of cardioprotection: challenges and opportunities - Proceedings of the 2010 NHLBI Workshop on Cardioprotection J Cardiovasc Pharmacol Ther 16 2011 223 232
95. Y. Lee, and A.B. Gustafsson Role of apoptosis in cardiovascular disease Apoptosis 14 2009 536 548
96. F. Eefting, B. Rensing, and J. Wigman Role of apoptosis in reperfusion injury Cardiovasc Res 61 2004 414 426
97. C.C. Smith, and D.M. Yellon Necroptosis, necrostatins and tissue injury J Cell Mol Med 15 2011 1797 1806
98. H. Yaoita, K. Ogawa, K. Maehara, and Y. Maruyama Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor Circulation 97 1998 276 281
99. T.A. Holly, A. Drincic, and Y. Byun Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo J Mol Cell Cardiol 31 1999 1709 1715
100. T. Okamura, T. Miura, and G. Takemura Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rat heart Cardiovasc Res 45 2000 642 650
101. M.M. Mocanu, G.F. Baxter, and D.M. Yellon Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury Br J Pharmacol 130 2000 197 200
102. J.Q. Huang, S. Radinovic, P. Rezaiefar, and S.C. Black In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia Eur J Pharmacol 402 2000 139 142
103. P. Kovacs, I. Bak, and L. Szendrei Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/reperfused rat hearts Naunyn Schmiedebergs Arch Pharmacol 364 2001 501 507
104. H. Ruetten, C. Badorff, C. Ihling, A.M. Zeiher, and S. Dimmeler Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects J Am Coll Cardiol 38 2001 2063 2070
105. S. Minatoguchi, T. Kariya, and Y. Uno Caspase-dependent and serine protease-dependent DNA fragmentation of myocytes in the ischemia-reperfused rabbit heart: these inhibitors do not reduce infarct size Jpn Circ J 65 2001 907 911
106. J.G. Chapman, W.P. Magee, H.A. Stukenbrok, G.E. Beckius, A.J. Milici, and W.R. Tracey A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2- methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury Eur J Pharmacol 456 2002 59 68
107. W.M. Yarbrough, R. Mukherjee, and G.P. Escobar Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway J Thorac Cardiovasc Surg 126 2003 1892 1899
108. Y. Chandrashekhar, S. Sen, R. Anway, A. Shuros, and I. Anand Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction J Am Coll Cardiol 43 2004 295 301
109. L.B. Balsam, T. Kofidis, and R.C. Robbins Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction J Surg Res 124 2005 194 200
110. J. Mersmann, P.A. Zacharowski, I. Schmitz, and K. Zacharowski Caspase inhibitor zVAD.fmk reduces infarct size after myocardial ischaemia and reperfusion in rats but not in mice Resuscitation 79 2008 468 474
111. W.M. Yarbrough, R. Mukherjee, and R.E. Stroud Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms J Cardiovasc Pharmacol 55 2010 408 416
112. M.S. Bhuiyan, and K. Fukunaga Activation of HtrA2, a mitochondrial serine protease mediates apoptosis: current knowledge on HtrA2 mediated myocardial ischemia/reperfusion injury Cardiovasc Ther 26 2008 224 232
113. L. Cilenti, Y. Lee, and S. Hess Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2 J Biol Chem 278 2003 11489 11494
114. H.R. Liu, E. Gao, and A. Hu Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion Circulation 111 2005 90 96
115. M.S. Bhuiyan, and K. Fukunaga Inhibition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo Eur J Pharmacol 557 2007 168 177
116. Q. Li, J. Li, and J. Ren UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK Am J Physiol Endocrinol Metab 297 2009 E965 E973
117. F. Di Lisa, and P. Bernardi Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole Cardiovasc Res 70 2006 191 199
118. D.J. Hausenloy, and D.M. Yellon The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion J Mol Cell Cardiol 35 2003 339 341
119. G. Heusch, K. Boengler, and R. Schulz Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection Basic Res Cardiol 105 2010 151 154
120. D.J. Hausenloy, S.B. Ong, and D.M. Yellon The mitochondrial permeability transition pore as a target for preconditioning and postconditioning Basic Res Cardiol 104 2009 189 202
121. T. Miura, M. Tanno, and T. Sato Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis Cardiovasc Res 88 2010 7 15
122. W. Nazareth, N. Yafei, and M. Crompton Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A J Mol Cell Cardiol 23 1991 1351 1354
123. E.J. Griffiths, and A.P. Halestrap Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts J Mol Cell Cardiol 25 1993 1461 1469
124. E.J. Griffiths, and A.P. Halestrap Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion Biochem J 307 Pt 1 1995 93 98
125. C. Weinbrenner, G.S. Liu, J.M. Downey, and M.V. Cohen Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia Cardiovasc Res 38 1998 678 684
126. F. Squadrito, D. Altavilla, and G. Squadrito Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats Eur J Pharmacol 364 1999 159 168
127. J. Minners, E.J. van den Bos, D.M. Yellon, H. Schwalb, L.H. Opie, and M.N. Sack Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection Cardiovasc Res 47 2000 68 73
128. D.J. Hausenloy, H.L. Maddock, G.F. Baxter, and D.M. Yellon Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55 2002 534 543
129. 2+-induced mitochondrial permeability transition Cardiovasc Res 61 2004 115 122
130. J.G. Krolikowski, M. Bienengraeber, D. Weihrauch, D.C. Warltier, J.R. Kersten, and P.S. Pagel Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels Anesth Analg 101 2005 1590 1596
131. S.Y. Lim, S.M. Davidson, D.J. Hausenloy, and D.M. Yellon Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore Cardiovasc Res 75 2007 530 535
132. L. Gomez, M. Paillard, H. Thibault, G. Derumeaux, and M. Ovize Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion Circulation 117 2008 2761 2768
133. R. Huhn, A. Heinen, N.C. Weber, M.W. Hollmann, W. Schlack, and B. Preckel Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore Br J Anaesth 100 2008 465 471
134. 2+-induced apoptosis through calcineurin dephosphorylation of BAD Science 284 1999 339 343
135. Y. Ikeda, T. Miura, and J. Sakamoto Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation Basic Res Cardiol 101 2006 418 426
136. B.G. Leshnower, S. Kanemoto, and M. Matsubara Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition Ann Thorac Surg 86 2008 1286 1292
137. P.C. Waldmeier, J.J. Feldtrauer, T. Qian, and J.J. Lemasters Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811 Mol Pharmacol 62 2002 22 29
138. L. Argaud, O. Gateau-Roesch, and D. Muntean Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury J Mol Cell Cardiol 38 2005 367 374
139. S.J. Clarke, G.P. McStay, and A.P. Halestrap Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A J Biol Chem 277 2002 34793 34799
140. D.J. Hausenloy, M.R. Duchen, and D.M. Yellon Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury Cardiovasc Res 60 2003 617 625
141. S.A. Javadov, S. Clarke, M. Das, E.J. Griffiths, K.H. Lim, and A.P. Halestrap Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart J Physiol 549 2003 513 524
142. L. Gomez, H. Thibault, and A. Gharib Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice Am J Physiol Heart Circ Physiol 293 2007 H1654 H1661
143. C. Piot, P. Croisille, and P. Staat Effect of cyclosporine on reperfusion injury in acute myocardial infarction N Engl J Med 359 2008 473 481
144. N. Mewton, P. Croisille, and G. Gahide Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction J Am Coll Cardiol 55 2010 1200 1205
145. A. Skyschally, R. Schulz, and G. Heusch Cyclosporine A at reperfusion reduces infarct size in pigs Cardiovasc Drugs Ther 24 2010 85 87
146. R.H. Lie, N. Stoettrup, E. Sloth, J.M. Hasenkam, R. Kroyer, and T.T. Nielsen Post-conditioning with cyclosporine A fails to reduce the infarct size in an in vivo porcine model Acta Anaesthesiol Scand 54 2010 804 813
147. L.O. Karlsson, A.X. Zhou, and E. Larsson Cyclosporine does not reduce myocardial infarct size in a porcine ischemia-reperfusion model J Cardiovasc Pharmacol Ther 15 2010 182 189
148. L.O. Karlsson, N. Bergh, L. Grip, and A. Cyclosporine 2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion J Cardiovasc Pharmacol Ther 15 2011 182 189
149. D. Hausenloy, E. Boston-Griffiths, and D. Yellon Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent Br J Pharmacol 165 2011 1235 1245
150. W.Y. Lim, C. Messow, and C. Berry Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis Br J Pharmacol 165 2011 2034 2043
151. M. Ruiz-Meana, J. Inserte, and C. Fernandez-Sanz The role of mitochondrial permeability transition in reperfusion-induced cardiomyocyte death depends on the duration of ischemia Basic Res Cardiol 106 2011 1259 1268
152. P.G. Jagtap, A. Degterev, S. Choi, H. Keys, J. Yuan, and G.D. Cuny Structure-activity relationship study of tricyclic necroptosis inhibitors J Med Chem 50 2007 1886 1895
153. X. Teng, A. Degterev, and P. Jagtap Structure-activity relationship study of novel necroptosis inhibitors Bioorg Med Chem Lett 15 2005 5039 5044
154. K. Wang, J. Li, A. Degterev, E. Hsu, J. Yuan, and C. Yuan Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5 Bioorg Med Chem Lett 17 2007 1455 1465
155. W. Zheng, A. Degterev, E. Hsu, J. Yuan, and C. Yuan Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7 Bioorg Med Chem Lett 18 2008 4932 4935
156. Y. Cho, T. McQuade, H. Zhang, J. Zhang, and F.K. Chan RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation PLoS One 6 2011 e23209
157. Z. You, S.I. Savitz, and J. Yang Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice J Cereb Blood Flow Metab 28 2008 1564 1573
158. D.M. Rosenbaum, A. Degterev, and J. David Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model J Neurosci Res 88 2010 1569 1576
159. G. Trichonas, Y. Murakami, and A. Thanos Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis Proc Natl Acad Sci U S A 107 2010 21695 21700
160. F.J. Northington, R. Chavez-Valdez, E.M. Graham, S. Razdan, E.B. Gauda, and L.J. Martin Necrostatin decreases oxidative damage, inflammation, and injury after neonatal HI J Cereb Blood Flow Metab 31 2011 178 189
161. X. Xu, K.W. Chua, C.C. Chua, C.F. Liu, R.C. Hamdy, and B.H. Chua Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury Brain Res 1355 2010 189 194
162. C.C. Smith, S.M. Davidson, S.Y. Lim, J.C. Simpkin, J.S. Hothersall, and D.M. Yellon Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther 21 2007 227 233
163. S.Y. Lim, S.M. Davidson, M.M. Mocanu, D.M. Yellon, and C.C. Smith The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore Cardiovasc Drugs Ther 21 2007 467 469
164. L. Lacerda, S. Somers, L.H. Opie, and S. Lecour Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway Cardiovasc Res 84 2009 201 208
165. J. Liu, A. van Mil, and K. Vrijsen MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1 J Cell Mol Med 15 2010 1474 1482
166. W.A. Noort, M.I. Oerlemans, and H. Rozemuller Human versus porcinemesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation J Cell Mol Med 16 8 2012 Aug 1827 1839
167. D.J. Hausenloy, and D.M. Yellon Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection Heart Fail Rev 12 2007 217 234
168. R.D. Lasley, J.W. Rhee, D.G. Van Wylen, and R.M. Mentzer Jr. Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart J Mol Cell Cardiol 22 1990 39 47
169. J.D. Thornton, G.S. Liu, R.A. Olsson, and J.M. Downey Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction Circulation 85 1992 659 665
170. V.J. McIntosh, and R.D. Lasley Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther 17 2011 21 33
171. E.D. Norton, E.K. Jackson, M.B. Turner, R. Virmani, and M.B. Forman The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury Am Heart J 123 1992 332 338
172. K.W. Mahaffey, J.A. Puma, and N.A. Barbagelata Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial J Am Coll Cardiol 34 1999 1711 1720
173. M. Marzilli, E. Orsini, P. Marraccini, and R. Testa Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction Circulation 101 2000 2154 2159
174. M. Quintana, P. Hjemdahl, and A. Sollevi Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study Eur J Clin Pharmacol 59 2003 1 9
175. A.M. Ross, R.J. Gibbons, G.W. Stone, R.A. Kloner, and R.W. Alexander A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) J Am Coll Cardiol 45 2005 1775 1780
176. M.L. Fokkema, P.J. Vlaar, and M. Vogelzang Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial Circ Cardiovasc Interv 2 2009 323 329
177. S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction Eur Heart J 29 2008 1485 1494
178. G. Takagi, K. Kiuchi, and T. Endo Alpha-human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs J Cardiovasc Pharmacol 36 2000 22 30
179. K. Sangawa, K. Nakanishi, K. Ishino, M. Inoue, M. Kawada, and S. Sano
180. X.M. Yang, S. Philipp, J.M. Downey, and M.V. Cohen Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts Basic Res Cardiol 101 2006 311 318
181. M.A. Rastegar, A. Vegh, J.G. Papp, and J.R. Parratt Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs Cardiovasc Drugs Ther 14 2000 471 479
182. A.K. Houng, R.A. McNamee, and A. Kerner Atrial natriuretic peptide increases inflammation, infarct size, and mortality after experimental coronary occlusion Am J Physiol Heart Circ Physiol 296 2009 H655 H661
183. M. Hayashi, T. Tsutamoto, and A. Wada Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction J Am Coll Cardiol 37 2001 1820 1826
184. H. Kuga, K. Ogawa, and A. Oida Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction Circ J 67 2003 443 448
185. S. Kasama, T. Toyama, and T. Hatori Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction J Am Coll Cardiol 49 2007 667 674
186. M. Kitakaze, M. Asakura, and J. Kim Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials Lancet 370 2007 1483 1493
187. J. Lonborg, N. Vejlstrup, and H. Kelbaek Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 12 2012 Jun 1491 1499
188. M.B. Davidson, G. Bate, and P. Kirkpatrick Exenatide Nat Rev Drug Discov 4 2005 713 714
189. M.H. Davidson Cardiovascular effects of glucagonlike peptide-1 agonists Am J Cardiol 108 2011 33B 41B
190. L.A. Nikolaidis, S. Mankad, and G.G. Sokos Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
191. L.A. Nikolaidis, D. Elahi, and T. Hentosz Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
192. L.A. Nikolaidis, D. Elahi, Y.T. Shen, and R.P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol 289 2005 H2401 H2408
193. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
194. L.A. Nikolaidis, A. Doverspike, and T. Hentosz Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines J Pharmacol Exp Ther 312 2005 303 308
195. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
196. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model Cardiovasc Drugs Ther 19 2005 9 11
197. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway Cardiovasc Drugs Ther 21 2007 253 256
198. D.P. Sonne, T. Engstrom, and M. Treiman Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart Regul Pept 146 2008 243 249
199. L. Timmers, J.P. Henriques, and D.P. de Kleijn Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury J Am Coll Cardiol 53 2009 501 510
200. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
201. K. Ban, K.H. Kim, and C.K. Cho Glucagon-like peptide (GLP)-1(9-36)amide- mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor Endocrinology 151 2010 1520 1531
202. M. Scholte, L. Timmers, and F.J. Bernink Effect of additional treatment with EXenatide in patients with an acute myocardial infarction (EXAMI): study protocol for a randomized controlled trial Trials 12 2011 240
203. D.B. Zorov, M. Juhaszova, and S.J. Sollott Mitochondrial ROS-induced ROS release: an update and review Biochim Biophys Acta 1757 2006 509 517
204. S. Javadov, M. Karmazyn, and N. Escobales Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases J Pharmacol Exp Ther 330 2009 670 678
205. R.M. Bell, and D.M. Yellon There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury Cardiovasc Ther 29 2010 e67 e79
206. N. Satoh, T. Sato, M. Shimada, K. Yamada, and Y. Kitada Lusitropic effect of MCC-135 is associated with improvement of sarcoplasmic reticulum function in ventricular muscles of rats with diabetic cardiomyopathy J Pharmacol Exp Ther 298 2001 1161 1166
207. 2+ in isolated ventricular muscles of rats with diabetic cardiomyopathy Mol Cell Biochem 249 2003 45 51
208. W.M. Yarbrough, R. Mukherjee, and G.P. Escobar Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion Ann Thorac Surg 76 2003 2054 2061
209. 2+ overload in ischemic/reperfused hearts Eur J Pharmacol 499 2004 179 187
210. 2+ handling modulator, limits infarct size of reperfused canine heart J Pharmacol Sci 103 2007 222 233
211. F.W. Bar, D. Tzivoni, and M.T. Dirksen Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study Eur Heart J 27 2006 2516 2523
212. I.K. Jang, N.J. Weissman, and M.H. Picard A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE) Am Heart J 155 2008 113 118
213. D. Tzivoni, J. Balkin, F.W. Bar, M. Hibberd, J.H. Reiber, and G. Cowing Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention Am J Cardiol 103 2009 1 4
214. F. Arslan, M.B. Smeets, and L.A. O'Neill Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody Circulation 121 2010 80 90
215. R.C. Lai, F. Arslan, and M.M. Lee Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury Stem Cell Res 4 2010 214 222